Anlotinib combined with mXELIRI as second-line treatment in advanced colorectal cancer pretreated with bevacizumab plus standard chemotherapy: A single-arm, phase IB/II study

被引：0
|
作者：
Qu, Xin
Chen, Xian
Li, Yong
Liu, Li-rong
Qu, Yan-chun
Hou, Fang-fang
Li, Wen-zhu
Liu, Yi-hong
Zhu, Yan-juan
Zhang, Haibo
机构：
[1] Guangdong Prov Hosp Chinese Med, Dept Oncol, Guangzhou, Peoples R China
[2] Guangdong Prov Hosp Chinese Med, Guangzhou, Peoples R China
[3] Guangdong Prov Hosp Chinese Med, Guangzhou, Guangdong, Peoples R China
[4] Guangdong Prov Hosp Tradit Chinese Med, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期
关键词：
D O I：
10.1200/JCO.2022.40.4_suppl.TPS220
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS220
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy
    Yong Sang Hong
    Jeeyun Lee
    Kyu-pyo Kim
    Jae-Lyun Lee
    Young Suk Park
    Joon Oh Park
    Se Hoon Park
    Sun Young Kim
    Ji Yeon Baek
    Jee Hyun Kim
    Keun-Wook Lee
    Tae-You Kim
    Tae Won Kim
    Investigational New Drugs, 2013, 31 : 183 - 191
  • [32] Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy
    Hong, Yong Sang
    Lee, Jeeyun
    Kim, Kyu-pyo
    Lee, Jae-Lyun
    Park, Young Suk
    Park, Joon Oh
    Park, Se Hoon
    Kim, Sun Young
    Baek, Ji Yeon
    Kim, Jee Hyun
    Lee, Keun-Wook
    Kim, Tae-You
    Kim, Tae Won
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (01) : 183 - 191
  • [33] A single-arm phase II clinical trial of anlotinib combined with chemotherapy for the treatment of metastatic triple-negative breast cancer
    Huang, Jia-Yi
    Xie, Xiao-Feng
    Chen, Xue-Lian
    Zhang, Qiu-Yi
    Chen, Li-Ping
    Bai, Xue
    Lan, Xiao-Feng
    Song, Lin
    Guo, Jin-Feng
    Du, Cai-Wen
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [34] Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial (oct, 10.1200/JCO-24-01266, 2024)
    Ahn, Daniel H.
    Ridinger, Maya
    Cannon, Timothy L.
    Mendelsohn, Lawrence
    Starr, Jason S.
    Hubbard, Joleen M.
    Kasi, Anup
    Barzi, Afsaneh
    Samuelsz, Errin
    Karki, Anju
    Subramanian, Ramanand A.
    Yemane, Divora
    Kim, Roy
    Wu, Chu-Chiao
    Croucher, Peter J. P.
    Smeal, Tod
    Kabbinavar, Fairooz F.
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (01) : 113 - 113
  • [35] A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients
    Kim, Youjin
    Kim, Tae Won
    Han, Sae Won
    Ahn, Joong Bae
    Kim, Seung Tae
    Lee, Jeeyun
    Park, Joon Oh
    Park, Young Suk
    Lim, Ho Yeong
    Kang, Won Ki
    CANCER RESEARCH AND TREATMENT, 2019, 51 (03): : 1128 - 1134
  • [36] A phase II single-arm pilot study of second-line icotinib treatment in advanced esophageal cancer with EGFR over-expression or amplification.
    Huang, Jing
    Fan, Qingxia
    Lu, Ping
    Ying, Jianming
    Ma, Changwu
    Liu, Wei
    Liu, Junfeng
    Liu, Ying
    Tan, Fenlai
    Sun, Yan
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [37] Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for advanced metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase II study
    Du, J.
    Tong, F.
    Sha, H.
    Sun, Y.
    Zhu, Y.
    Qi, L.
    Li, X.
    Li, W.
    Yang, Y.
    Li, Z.
    Xu, C.
    Ni, J.
    Zhang, X.
    Zhu, C.
    Wang, X.
    Qian, X.
    Liu, B.
    ANNALS OF ONCOLOGY, 2023, 34 : S1535 - S1535
  • [38] Feasibility and tolerability of sintilimab plus anlotinib as the second-line therapy for patients with advanced biliary tract cancers: An open-label, single-arm, phase II clinical trial
    Jin, Shuiling
    Zhao, Ruihua
    Zhou, Chuang
    Zhong, Qian
    Shi, Jianxiang
    Su, Chang
    Li, Qinglong
    Su, Xiaoxing
    Chi, Huabin
    Lu, Xu
    Jiang, Guozhong
    Chen, Renyin
    Han, Jinming
    Jiang, Miao
    Qiao, Shishi
    Liu, Jingjing
    Song, Min
    Song, Lijie
    Du, Yabing
    Chang, Zhiwei
    Wang, Meng
    Dong, Meilian
    Zhong, Yali
    Yu, Pu
    Zhang, Xiaojian
    Zong, Hong
    INTERNATIONAL JOURNAL OF CANCER, 2023, 152 (08) : 1648 - 1658
  • [39] A single-arm, open-label, prospective, multicenter study of apatinib combined with chemotherapy as second-line therapy in patients with advanced gastric cancer
    Feng, J.
    Shen, B.
    Xu, J.
    Wang, Q.
    Ling, G.
    Mao, Y.
    Cai, M.
    Yang, Y.
    Mei, J.
    Han, Z.
    Wu, Y.
    Shi, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S913 - S913
  • [40] Phase II study of raltitrexed (Tomudex) as second-line treatment in advanced colorectal cancer (ACC)
    Santoro, M
    Santoro, A
    Maiorino, L
    Forestieri, V
    Forestieri, P
    ANNALS OF ONCOLOGY, 1998, 9 : 45 - 45
12345